Medpace Holdings, Inc. with ticker code (MEDP) have now 7 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $480.00 and $395.00 with the average share target price sitting at $447.43. (at the time of writing). Given that the stocks previous close was at $394.10 and the analysts are correct then we can expect a percentage increase in value of 13.5%. Also worth taking note is the 50 day moving average now sits at $394.15 and the 200 moving average now moves to $326.98. The market cap for the company is 12.01B. The stock price for the company is currently $387.53 USD
The potential market cap would be $13,631,620,098 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 39.5, revenue per share of $63.98 and a 13.89% return on assets.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
